What question did this study set out to answer?

April 1, 2026Open Access

Case ReportSpontaneous regression of methotrexate-related lymphoproliferative disorders in rheumatoid arthritis: reports of three cases followed for up to 5 years

JMJuntaro MARUYAMA JNJun NakamuraOsaka University of Economics KNKento NawataChiba University

Key Points

To report on cases of spontaneous regression of methotrexate-related lymphoproliferative disorders in rheumatoid arthritis patients after MTX discontinuation.
Case report on three patients with MTX-related lymphoproliferative disorder
Patients diagnosed through imaging and biopsy evaluations
Follow-up duration up to 5 years after treatment cessation
All three patients showed resolution of lymphoproliferative disorders after stopping methotrexate
No recurrence observed in a follow-up period of up to 5 years
Definitive diagnoses made through imaging and bronchoscopic biopsy

Abstract

ABSTRACTMethotrexate-related lymphoproliferative disorder (MTX-LPD) is a serious complication of methotrexate (MTX) treatment in patients with rheumatoid arthritis. We treated 3 patients with MTX-LPD associated with rheumatoid arthritis. Patient 1 was a 55-year-old woman whose chest X-ray showed abnormal shadows 16 years after she started MTX treatment. Patient 2 was a 63-year-old woman who had signs/symptoms of viral rhinitis and whose chest X-ray showed multiple shadows and lung infiltrates. A definitive diagnosis of MTX-LPD was obtained from a bronchoscopic biopsy specimen. Patient 3 was a 44-year-old woman whose chest computed tomography scans showed incidental bilateral axillary lymphadenopathy after anaphylactic shock associated with an injection of a biosimilar of infliximab. After MTX discontinuation, the LPD resolved in all 3 patients and has not recurred through up to 5 years of follow-up.

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper